Stockscreener 앱 받기
1.10
0.00%
0.00
전일 마감가:
$1.10
열려 있는:
$1.11
하루 거래량:
16,324
Relative Volume:
0.10
시가총액:
$46.22M
수익:
-
순이익/손실:
$-32.00M
주가수익비율:
-0.7247
EPS:
-1.5178
순현금흐름:
$-4.66M
1주 성능:
+6.80%
1개월 성능:
+19.57%
6개월 성능:
-22.54%
1년 성능:
+27.89%
1일 변동 폭
$1.10
$1.11
1주일 범위
$1.00
$1.14
52주 변동 폭
$0.8424
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.10 | 46.22M | 0 | -32.00M | -4.66M | -1.5178 |
LLY
Lilly Eli Co
|
919.45 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.91 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.01 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
196.01 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.98 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds ExpectationsPrice Target - Cổng thông tin điện tử Tỉnh Sơn La
MIRA Pharmaceuticals (MIRA) Top Loser | Q3 2025: Profit SurprisesP/B Ratio - Cổng thông tin điện tử Tỉnh Sơn La
Stock List: Research Stocks from Around the World - GuruFocus
MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
Aug Summary: How does MIRA Pharmaceuticals Inc compare to its peersWeekly Investment Recap & AI Driven Stock Movement Reports - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | K6S | US60458C1045 - marketscreener.com
MIRA Pharmaceuticals : Investor Presentation - marketscreener.com
MIRA Technical Analysis & Stock Price Forecast - Intellectia AI
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investment Report: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez - 富途牛牛
Mira Pharmaceuticals Inc (K6S.MU) stock price, news, quote and history - Yahoo Finance UK
MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan
MIRA Should I Buy - Intellectia AI
Cash strain and trial progress at MIRA Pharmaceuticals (NASDAQ: MIRA) - Stock Titan
Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44)M Net Loss - tradingview.com
MIRA Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MIRA Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
What's going on with MIRA Pharma stock Tuesday? - MSN
Institution Moves: Can MIRA Pharmaceuticals Inc deliver alphaWeekly Gains Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Analyst Downgrade: What are MIRA Pharmaceuticals Incs recent SEC filings showing2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Retail Surge: Is MIRA Pharmaceuticals Inc a strong growth stockMarket Growth Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.Common Stock (NQ:MIRA) - FinancialContent
What's Going On With MIRA Pharma Stock Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
MIRA’s Mira-55 shows no CNS side effects in preclinical tests By Investing.com - Investing.com India
MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55 - TipRanks
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - The Desert Sun
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment - Minichart
Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com India
MIRA’s Mira-55 shows no CNS side effects in preclinical tests - investing.com
MIRA Pharmaceuticals (MIRA) posts Mira-55 CNS and pain preclinical data - Stock Titan
MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan
Aug EndMonth: What is the Moat Score of MIRA Pharmaceuticals Inc2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Momentum Shift: Can MIRA Pharmaceuticals Inc maintain its current growth rateRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Macro Review: Can MIRA Pharmaceuticals Inc maintain its current growth rateTrade Ideas & Reliable Price Breakout Signals - baoquankhu1.vn
Dividend Watch: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat
Aug Ideas: What is the Moat Score of MIRA Pharmaceuticals IncTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
0.07%
자본화:
|
볼륨(24시간):